Clinical Trials Sponsored by Merck Ltd.

Total 21985 results

Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea (ECOS KOR)

Growth Disorders

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)

Heart Failure, Congestive

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

Infertility

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control (GIANT)

Hypertension | Diabetes Mellitus, Type II

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])

Hypertension

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients. (ABBA)

Chronic Heart Failure

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Carcinoma, Squamous Cell

India
Merck KGaA, Darmstadt, Germany
Merck Ltd., Thailand

Terminated

Glucophage XR® Observational Study

Diabetes Mellitus Type 2 | GI Side Effect

Thailand
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Colorectal Neoplasms

India
Merck KGaA, Darmstadt, Germany
Merck Ltd., Taiwan

Terminated

Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen

Infertility

Taiwan
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd.

Terminated

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Infertility

China
Merck KGaA, Darmstadt, Germany
Merck Pte. Ltd., Singapore

Completed

An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)

Infertility

Singapore
Merck KGaA, Darmstadt, Germany
Merck Pte. Ltd., Singapore

Completed

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (APEC)

Metastatic Colorectal Cancer

Singapore
Merck KGaA, Darmstadt, Germany
Merck Pte. Ltd., Singapore

Completed

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

Hypogonadism

China
Merck KGaA, Darmstadt, Germany
Merck Ltd., Taiwan; Merck Pte. Ltd., Singapore; PT Merck Tbk., Indonesia, an...

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore) (ECOS TW ID SG)

Growth Disorders

Singapore, Taiwan, Indonesia
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation (ARTIST)

Polycystic Ovary Syndrome

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment (ECOS CHN)

Growth Disorders

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Terminated

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Hepatocellular Carcinoma | Advanced Solid Tumors

Japan
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients (CREATIVE)

Hypertension

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

Dwarfism, Pituitary
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Terminated

Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants (SPET)

Non-obstructive Coronary Artery Disease

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Terminated

Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants (Biso-CHF)

Heart Failure

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension

Hypertension

China
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Terminated

Colposeptine for the Treatment of Bacterial Vaginosis

Vaginosis, Bacterial

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease (RESPOND)

Non-Obstructive Coronary Artery Disease

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia (ECOS AUS)

Growth Disorders

Australia
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina (SIGMART)

Coronary Disease | Stable Angina

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Polycystic Ovarian Syndrome | Anovulation | Oligo-ovulation | Hypothalamic-pituitary Dysfunction

Japan
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Non-small Cell Lung Cancer

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women

Infertility | Ovulation Induction

Japan
BioLineRx, Ltd.
Merck Sharp & Dohme LLC

Completed

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT)

Metastatic Pancreatic Adenocarcinoma

United States, Israel, Korea, Republic of, Spain
Teclison Ltd.
Merck Sharp & Dohme LLC

Recruiting

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Colorectal Cancer; Lung Cancer

Taiwan, United States
EMD Serono
Merck Pte. Ltd., Singapore

Completed

A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Hepatitis C
Organon and Co
Merck Frosst Canada Ltd.

Terminated

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Atherosclerosis | Hypercholesterolemia
University of Alberta
Merck Frosst Canada Ltd.

Withdrawn

On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)

Benign Prostatic Hyperplasia

Canada
TiumBio Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Solid Tumor

United States
Qurient Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Hepatocellular Cancer

Korea, Republic of, United States
InventisBio Co., Ltd
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate D-1553 in Subjects With Solid Tumors

NSCLC | Solid Tumor, Adult | CRC

United States, Taiwan, Australia, Korea, Republic of
Opal Rheumatology Ltd.
Merck Sharp & Dohme LLC

Unknown

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Australia
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
Qurient Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Metastatic Cancer | Advanced Cancer

United States, Korea, Republic of
Nectin Therapeutics Ltd
Merck Sharp & Dohme LLC

Recruiting

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Cancer | Metastatic Cancer | Advanced Solid Tumor | Tumor, Solid | Locally Advanced Solid Tumor

United States, Israel
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaborators

Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PERSIST)

Assisted Reproductive Techniques | Reproductive Technology, Assisted

Italy, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
AUM Biosciences Pte Ltd
Merck Sharp & Dohme LLC

Recruiting

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Australia
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC; Iqvia Pty Ltd

Completed

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. (IVIVC)

Malignant Solid Tumor

Belgium

3

Subscribe